← Back
Data updated: Mar 29, 2026
EIRGEN
OncologyMetabolic
Pharma
EIRGEN is a pharmaceutical company focused on Oncology, Metabolic. Key products include RAYALDEE.
2016
Since
3
Drugs
-
Trials
17
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
TEMOZOLOMIDE 2026-01-22
Labeling
TEMOZOLOMIDE 2026-01-22
Labeling
CYCLOPHOSPHAMIDE 2025-07-11
Labeling
TEMOZOLOMIDE 2025-07-01
Labeling
CYCLOPHOSPHAMIDE 2025-03-11
Labeling
CYCLOPHOSPHAMIDE 2024-12-30
Labeling
CYCLOPHOSPHAMIDE 2024-12-26
CYCLOPHOSPHAMIDE 2024-12-19
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 71%
1 drugs Phase 3: 2 Phase 1: 1
Metabolic 29%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2016-02-10
- Latest
- 2024-12-03
- Applications
- 3